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Abstract Id2 and cyclin D1 share several biological activities,
including inhibition of di¡erentiation, stimulation of the G1^S
transition in the cell cycle and stimulation of tumorigenesis.
Mammary glands of Id23=3 mice display severely impaired lo-
bulo-alveolar development during pregnancy, similarly to those
of cyclin D1 null females. We investigated the functional rela-
tionship between Id2 and cyclin D1 in the mammary gland.
Id23=3 mammary glands expressed a normal level of cyclin
D1. No direct interaction of Id2 with cyclin D1 or its binding
partner cdk4 was detected in mammalian two-hybrid assays.
Ectopic expression of a cyclin D1 transgene did not rescue the
mammary phenotype of Id23=3 mice. These results suggest that
Id2 acts downstream or independently of cyclin D1 in the con-
trol of mammary cell proliferation during pregnancy.
* 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Mammary epithelial cells proliferate rapidly during preg-
nancy under the in£uence of various hormones and growth
factors and form an expanded glandular structure via the pro-
cess of lobulo-alveolar development, providing a good exper-
imental model system for studying the mechanism of cell pro-
liferation in vivo [1]. Loss-of-function experiments in mice
have revealed several genes that are involved in the process
of lobulo-alveolar development and carcinogenesis [2^6].
The four Id proteins (Id1^Id4) are negative regulators of
basic helix-loop-helix transcription factors that play a pivotal
role in multiple processes of cell di¡erentiation, proliferation
and other functions [7,8]. They are crucial for cell prolifera-
tion due to their ability to stimulate the G1^S transition in the
cell cycle [8^13], although the precise mechanism of this stim-
ulation has not been fully elucidated. The in vivo functions of
Ids in cell cycle control have been con¢rmed by gene-targeting
experiments in mice [5,14,15]. We previously reported that
Id2-de¢cient female mice show a lactation defect due to im-
paired lobulo-alveolar development of their mammary glands
during pregnancy. The observed defect is intrinsic to epithelial
cells and mostly due to the impaired proliferation of these
cells during early pregnancy [5]. Interestingly, the impaired
proliferation of Id23=3 mammary epithelial cells at 7 days
post coitus (d.p.c.) is restored at 10 d.p.c. [5]. This time point
coincides with the augmented expression of cyclin D1 in
Id23=3 mammary epithelial cells [5], suggesting the possibility
that forced expression of cyclin D1 can rescue the mammary
defect of Id23=3 mice.
Cyclin D1 belongs to the D-type cyclins, and speci¢cally
heterodimerizes with and activates cyclin-dependent kinases
(cdks), cdk4 or cdk6, in the G1 phase of mammalian cells
[16^18]. Several lines of evidence have suggested functional
similarity of cyclin D1 and Id2 in the cell cycle, although their
relationship remains unclear. Of particular note, mice with
cyclin D1 de¢ciency show a mammary phenotype similar to
that of Id2 null mice [4,5]. This observation raises the possi-
bility of the collaboration of Id2 with cyclin D1 in mammary
gland development. On the other hand, it is reported that
enhanced expression of Id2 is associated with an inhibition
of cyclin D1 expression, raising another possibility that the
balance between Id2 and cyclin D1 is important in cell cycle
regulation [19].
In this study we investigated the functional relationship of
Id2 and cyclin D1 in vivo using a genetic approach and found
that crossing with mammary epithelial speci¢c cyclin D1
transgenic mice does not rescue the phenotype of Id2-de¢cient
mice. Our results suggest that Id2 functions independently or
downstream of cyclin D1 in the control of proliferation of
pregnant mammary epithelial cells in vivo.
2. Materials and methods
2.1. Mice
Mouse mammary tumor virus (MMTV)-D1-transgenic (FVB/N)
and Id2-de¢cient mice (129/SvUNMRI) have been described previ-
ously [6,20]. Transheterozygous females generated by crossing be-
tween the two mouse lines were further crossed with Id23=3 males
to obtain mice heterozygous or nullizygous for Id2 and transgenic
(+/Tg) or non-transgenic (+/+) for cyclin D1. No di¡erence has
been observed in mammary gland development between Id2þ=3 and
Id2þ=þ female mice.
2.2. Tissue preparations and histology
Inguinal mammary glands (#4) were used for all experiments.
Mammary glands were ¢xed with Carnoy’s ¢xative for whole-mount
analyses or with 4% paraformaldehyde in phosphate-bu¡ered saline
0014-5793 / 03 / $22.00 K 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)00906-2
*Corresponding author. Fax: (81)-776-618164.
E-mail address: yyokota@fmsrsa.fukui-med.ac.jp (Y. Yokota).
Abbreviations: AD, transactivation domain; BD, DNA binding do-
main; BrdU, bromodeoxyuridine; cdk, cyclin-dependent kinase;
CK18, cytokeratin 18; d.p.c., days post coitus; MMTV, mouse mam-
mary tumor virus; pRb, retinoblastoma protein; RT-PCR, reverse
transcription-polymerase chain reaction; Tg, transgenic
FEBS 27594 27-8-03
FEBS 27594 FEBS Letters 551 (2003) 123^127
for bromodeoxyuridine (BrdU) incorporation analyses, and further
processed as described previously [5]. For immunohistochemistry,
5-Wm-thick para⁄n-embedded sections of 7 d.p.c. mammary glands
were reacted with antibodies against cyclin D1 (DCS-6, BD Bioscien-
ces Pharmingen) and cyclin A2 (C-19; Santa Cruz Biotechnology),
followed by HRP-conjugated anti-rabbit IgG and anti-mouse IgG
antibodies (EnVision, Dako), respectively. Detection was done as de-
scribed [5].
2.3. RNase protection, reverse transcription-polymerase chain reaction
(RT-PCR), Northern and Western blot analyses
RT-PCR, Northern blot and RNase protection assays were carried
out using standard protocols as previously described [5,21]. The prim-
er sets used in RT-PCR were designed according to the sequences
deposited in GenBank. Cytokeratin 18 (CK18) cDNA, used in North-
ern blot analysis, was derived from pBluecBSE [22]. The template sets
for RNase protection were mCYC-1 and mCYC-2 (BD Biosciences).
Immunoblot analyses were performed as previously described [21].
Antibodies used in this study were FITC-labeled anti-cyclin D1 anti-
body (CC12F; Oncogene), anti-cyclin A2 antibody (C-19; Santa Cruz
Biotechnology) and anti-E-cadherin antibody (ECCD-2; TaKaRa).
2.4. Mammalian two-hybrid assay
Plasmids were constructed with pcBZ05.4 (cyclin D1, [18]), pBS-
cdk4 [18], pCMV-Id2 and pCMV-E12 [21] based on pCMV-AD
and pCMV-BD (Stratagene). Plasmids were transfected into
NIH3T3 cells by lipofection and luciferase assays were performed
using the Dual-Luciferase Reporter Assay System (Promega) as pre-
viously described [21].
3. Results
To elucidate the e¡ect of Id2 de¢ciency on cell cycle regu-
lation in pregnant mammary glands, we studied the expression
of cyclins in virgin and 7 d.p.c. mammary glands of Id2-de¢-
cient mice, because mammary epithelial cell proliferation is
stimulated in the early phase of pregnancy [1], when Id23=3
mice show a defect in mammary glands [5]. Pregnancy up-
regulated the mRNA expression of cyclins A2, B1 and D1
more than two-fold in the control glands (Fig. 1A). The levels
of cyclin mRNAs were not down-regulated in either virgin or
7 d.p.c. mammary glands of Id23=3 females (Fig. 1A), even
though Id23=3 mammary epithelial cells clearly show retarded
cell proliferation at 7 d.p.c. [5]. The protein level of cyclin D1
was also normal in Id23=3 females (Fig. 1B). We noticed that
the amount of cyclin A2 protein was decreased in virgin but
similar in 7 d.p.c. Id2 null glands compared to that in the
control glands (Fig. 1B). Immunohistochemically, cyclin A2
and D1 proteins were mainly detected in mammary epithelial
cells in both Id2þ=3 and Id23=3 mice (Fig. 1C). In addition,
RT-PCR analyses showed similar expression levels of cdk4
and cdk6 mRNAs between Id2þ=3 and Id23=3 mammary
glands (data not shown). These results indicate that Id2 de¢-
ciency does not a¡ect the expression of cyclin D1 or the other
cell cycle-related factors examined.
To examine whether Id2 interacts with cyclin D1 at the
protein level, cyclin D1 and Id2 were fused to the NF-UB
transactivation domain (AD) or GAL4 DNA binding domain
(BD) and analyzed with mammalian two-hybrid assays using
NIH3T3 cells. As shown in Fig. 2, no apparent interaction
was detected between AD-cyclin D1 and BD-Id2 (1.4-fold
induction), although robust interactions between Id2 and
E12 protein, a dimerization partner of Id proteins (AD-
E12(bHLH)/BD-Id2; 115, AD-Id2/BD-E12(bHLH); 30-
fold), and between cyclin D1 and cdk4/6 (AD-cyclin D1/
BD-cdk4; 58, AD-cyclin D1/BD-cdk6; 71-fold) were detected
(Fig. 2 and data not shown). In addition, we also failed to
observe an interaction of AD-Id2 with BD-cdk4 or cdk6 (0.6-
and 1.0-fold, respectively, Fig. 2 and data not shown). Re-
garding the switched combinations, namely AD-Id2/BD-cyclin
D1 and AD-cdk4/BD-Id2, we could not detect apparent in-
Fig. 1. Normal expression of cyclins in Id23=3 mammary glands.
Expression of genes and proteins, indicated on the left, was ana-
lyzed in Id2þ=3 and Id23=3 mammary glands at the indicated d.p.c.
Genotypes are indicated at the top of each lane. A: RNase protec-
tion assays for gene expression of various cyclins (cycs) in Id23=3
mammary glands. RNAs isolated from 8 to 10 mice at the indicated
times were combined and analyzed. Genes and genotypes are indi-
cated on the left and the top, respectively. The results of Northern
analysis of CK18 are shown at the bottom. CK18 was used as a
marker of epithelial cells. Relative expression levels of cyclins com-
pared to that of CK18 are shown on the right. The relative level of
expression in virgin heterozygous mice was designated as 100%.
B: Western blot analysis of cyclins A2 and D1 and in Id23=3 mam-
mary glands. E-cadherin (E-cad) was used as an epithelial marker.
Protein was extracted from the mammary glands of three individu-
als, combined and analyzed. Proteins and genotypes are indicated
on the left and the top, respectively. Relative expression levels of cy-
clins A2 and D1 compared with E-cadherin are shown on the right.
The relative level of expression in virgin heterozygous mice was des-
ignated as 100%. C: Immunohistochemistry for cyclins A2 and D1
in mammary glands. Genotypes and detected cyclins are indicated
on the left and the top, respectively. The presence or absence of the
respective primary antibodies (1st Ab) are shown in the middle.
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teractions. Since we failed to detect the interaction between
BD-cyclin D1 and AD-cdk4 in this system (data not shown),
BD-cyclin D1 and/or AD-cdk4 may loss their original prop-
erty due to the formation of fusion proteins. These observa-
tions suggest that Id2 does not interact directly with cyclin D1
or cdk4/6.
To investigate the functional relationship between Id2 and
cyclin D1 in vivo, we performed crossing experiments of Id2-
de¢cient mice with mammary-speci¢c cyclin D1 transgenic
mice that ectopically express human cyclin D1 in mammary
epithelial cells under the control of the MMTV 5P long termi-
nal repeat [6]. This transgene has been reported to be able to
rescue the mammary gland phenotype of mice with mutated
IKKK [23]. The human cyclin D1 expression in the transgenic
mice was con¢rmed by RT-PCR using a primer set speci¢c to
the transgene at 7 d.p.c. and on the ¢rst day of lactation
irrespective of the Id2 genotype (Fig. 3A). Furthermore, im-
munohistochemistry con¢rmed the transgenic protein expres-
sion in mammary epithelial cells (data not shown). Thus, the
transgene was expressed in mammary epithelial cells as ex-
pected.
On the day of parturition, we performed whole-mount anal-
yses of mammary glands of crossed mice. The MMTV-cyclin
D1 transgene itself had no e¡ect on the developmental process
of the mammary glands in Id2þ=3 females during pregnancy
compared to the lobulo-alveolar development in non-trans-
genic Id2þ=3 mammary glands (Fig. 3B). As described previ-
ously [5], the mammary glands of non-transgenic Id2 nullizy-
gous mice showed normal side-branching but failed to develop
the lobulo-alveolar compartment during pregnancy (Fig. 3B).
Similarly the glandular structure was poorly developed in
+/Tg; Id23=3 mammary gland after delivery (Fig. 3B). Re-
peated pregnancies did not improve the situation (data not
shown). These results indicate that transgenic expression of
cyclin D1 does not rescue the failure of mammary glands of
Id23=3 mice and suggest that cyclin D1 is not a downstream
factor of Id2 function in the lobulo-alveolar development dur-
ing pregnancy.
We ¢nally performed BrdU incorporation assays at 7 d.p.c.,
a time when Id2 null mammary epithelium shows a signi¢cant
proliferation arrest [5]. In cyclin D1 transgenic Id2þ=3 mam-
mary glands, the percentage of BrdU-positive epithelial cells
was similar to that in non-transgenic Id2 heterozygous glands
(Table 1). This observation indicates that ectopic expression
of cyclin D1 does not in£uence the proliferation of normal
pregnant mammary epithelial cells. As expected from the re-
sults of whole-mount analyses, Id23=3 cells incorporated
BrdU less e¡ectively than Id2 heterozygous mammary cells
did, irrespective of the presence or absence of the cyclin D1
transgene (Table 1). These data demonstrate that the ectopic
expression of cyclin D1 does not overcome the proliferation
disturbance or the developmental defect of Id23=3 epithelial
cells during pregnancy.
4. Discussion
Several lines of evidence suggest that D-type cyclins and Id
proteins share similar features and functions in the regulation
of proliferation, which prompted us to investigate the func-
Fig. 2. Lack of interaction of Id2 with cyclin D1 and cdk4 in mam-
malian two-hybrid assays. AD- and BD-fusion proteins are listed on
the left. The results are expressed as fold stimulation relative to the
value of each BD-fusion protein with AD alone based on the mean
of triplicate samples. Representative data from one of four indepen-
dent experiments are shown.
Fig. 3. Forced expression of cyclin D1 does not rescue the failure of
mammary gland development caused by Id2 de¢ciency. A: RT-PCR
analysis of expression of the cyclin D1 transgene in Id23=3 mam-
mary glands. The analyses detected the transcript from the trans-
gene, the endogenous murine gene, or both selectively, as indicated
on the left. RNA used for the analyses was prepared at the indi-
cated times. L1, the ¢rst day of lactation. CK18 was used as a
marker of epithelium. L-actin was included as an internal control.
Genotypes are indicated at the top. B: Whole-mount analyses of
mammary glands of crossed mice. Representative results are shown.
Genotypes are indicated at the top (Id2 locus) and the left
(MMTV-D1 locus).
Table 1
Results of BrdU incorporation assay
Id2þ=3 Id23=3
+/+ 9.8 3.7
9.5 2.4
+/Tg 7.7 3.7
8.4 3.3
The results indicate the percentages of BrdU-labeled cells obtained
from two individuals in each mouse group. Approximately 1000 nu-
clei of epithelial cells were examined in each sample taken at 7 d.p.c.
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tional relationship between cyclin D1 and Id2. Both of these
proteins are expressed in a variety of undi¡erentiated and
proliferating cells in vivo and are induced after serum stimu-
lation in cultured cells. Each protein possesses the ability to
inhibit cell di¡erentiation and stimulates progression of the
cell cycle, especially by its functioning in the phase of G1^S
transition in cultured cells [8,13,16,17]. Loss-of-function ex-
periments in mice have demonstrated the requirement for cy-
clin D or Id for the proliferation of several cell types in vivo,
in particular for the proliferation of mammary epithelial cells
during pregnancy [4,5,14,15]. They are involved in tumorigen-
esis as well as in normal cell proliferation. The expression of
D-type cyclin or Id proteins is up-regulated in cultured cells in
response to oncogenic stimuli [8,13,16]. Cyclin D1 overexpres-
sion can be detected in various kinds of primary human can-
cer lesions, including more than 50% of breast cancers with or
without ampli¢cation of the gene [24]. Increased expression of
Id proteins has been reported in primary human tumors as
well as in cultured tumor cells, although alteration of the Id
gene loci has not been detected so far [8,13]. Moreover, ec-
topic expression of cyclin D or Id by transgenesis leads to
tumor formation in mice [6,25^27].
MyoD, a bHLH factor of muscle cells, has been reported to
bind cdk4 directly. Cdk4 prevents MyoD from binding to
DNA, and conversely, MyoD inhibits the activity of cyclin
D1/cdk4 [28,29]. This observation suggests that the cyclin
D1/cdk4 activity may be regulated by a tissue-speci¢c
bHLH factor in the mammary gland. Such a bHLH factor
could be a target of Id2. However, we have failed to identify
such a factor by degenerate PCR [5] and another group failed
to do so by yeast two-hybrid analysis [30]. Based on these
facts, we examined here the possibility of a direct interaction
between Id2 and cyclin D1 or cdk4/6. However, neither cyclin
D1 nor cdk4/6 showed a direct protein^protein interaction
with Id2 in mammalian two-hybrid assays. Moreover, Id2
did not modulate the binding a⁄nity of cyclin D1 for cdk4
(data not shown). Therefore, it is not likely that Id2 regulates
cyclin D1/cdk4 activity by direct protein interaction.
We demonstrated that the forced expression of cyclin D1
could not substitute for Id2 in the proliferation of mammary
cells or in lobulo-alveolar development, suggesting that cyclin
D1 is not a downstream factor of Id2 in pregnant mammary
epithelial cells. What, then, is the relationship between Id2
and cyclin D1 in mammary gland development? One possibil-
ity is that the function of Id2 is separate from that of cyclin
D1, but that the functions of Id2 and cyclin D1 might ulti-
mately converge on the promotion of cell proliferation. Cyclin
D1 inactivates a pocket domain protein such as retinoblasto-
ma protein (pRb) by phosphorylation, leading to the release
of an E2F transcription factor [16^18,31,32]. Since Id2 has
been shown to have an antagonistic activity against pocket
domain proteins via its direct binding [10], a pocket domain
protein seems to be a candidate as the common target. How-
ever, the expression levels of E2F-downstream genes, includ-
ing cyclin D1, cyclin E, DHFR, E2F1 and E2F2 [16,32], are
not altered in Id2-de¢cient mammary glands (this study and
data not shown), suggesting that the pRb/E2F pathway is not
perturbed in Id2 null mammary cells. Alternatively, it is also
possible that cyclin D1 may regulate Id2 activity. For exam-
ple, cyclin D1 activates cyclin E expression and cyclin E/cdk2
activity through regulation of the pRb/E2F pathway
[16,17,32]. The cyclin E/cdk2 complex can phosphorylate the
serine residue at the ¢fth amino acid position in Id2 and
weaken the binding a⁄nity of Id2 for an E protein, leading
to the progression of cells from G1 to S phase [33].
Recent studies using genetically engineered mice have re-
vealed that there are two categories of genes involved in mam-
mary gland development: one for lobulo-alveolar develop-
ment (ex. Stat5a and Id2) and the other for predisposition
to mammary tumors (ex. c-myc and Wnt) [2,3]. In contrast
to cyclin D1 that belongs to both categories, it is currently
unclear whether Id2 is involved in mammary tumorigenesis. If
Id2 functions as a downstream factor of cyclin D1 directly or
indirectly in mammary epithelial cell proliferation, the inci-
dence of cyclin D1-induced mammary tumor formation [6]
may be decreased by deletion of Id2. We are now investigating
the incidence of such tumors in the crossed mice to examine
this possibility.
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